Key result
Nebivolol linked to ~27% lower all-cause mortality and greater BP reductions versus other beta blockers.
Why the study?
Comparative data on different beta blockers for hypertension remain limited, and the real-world effectiveness and clinical outcomes of nebivolol required evaluation.
Does nebivolol improve blood pressure control and reduce major adverse cardiovascular events in patients with hypertension compared to other beta blockers?
Does nebivolol improve blood pressure control and reduce major adverse cardiovascular events in patients with hypertension compared to other beta blockers?
In hypertensive patients without heart failure, nebivolol was associated with superior blood pressure and heart rate reductions, as well as lower risks of mortality and MACE, compared to other beta blockers.
May support nebivolol preference in hypertension without HF; leaves open randomized confirmation of superiority.
Background Beta blockers represent an important class of antihypertensive agents, but comparative data on different beta blockers in the treatment of hypertension remain limited. Nebivolol, a third‐generation beta blocker, possesses unique pharmacological properties. This study aimed to evaluate its real‐world effectiveness in blood pressure and heart rate control, as well as the associated clinical outcomes in patients with hypertension. Methods We conducted a retrospective review of the Chang Gung Research Database to identify patients with hypertension who were newly prescribed beta blockers—primarily nebivolol, carvedilol, and bisoprolol—between 2018 and 2023. Inverse probability of treatment weighting was applied to balance the baseline characteristics across groups. Outcomes included changes in blood pressure and heart rate, as well as the incidence of major adverse cardiovascular events. Results We identified 99 942 patients with hypertension. After inverse probability of treatment weighting, the patients treated with nebivolol had significantly greater reductions in systolic blood pressure (−11.0 mm Hg [95% CI, −11.6 to −10.4]), diastolic blood pressure (−8.1 mm Hg [95% CI, −8.5 to −7.6]), and heart rate (−7.3 bpm [95% CI, −7.8 to −6.9]) compared with carvedilol and other beta blockers. During a mean follow‐up of 4.5 years, nebivolol use was associated with a significantly lower risk of all‐cause mortality (hazard ratio [HR], 0.73 [95% CI, 0.63–0.86]) and major adverse cardiovascular events (HR, 0.81 [95% CI, 0.74–0.90]). Conclusions In this retrospective cohort study of patients with hypertension without heart failure, nebivolol was associated with greater reductions in blood pressure and heart rate, as well as a lower risk of all‐cause mortality and major adverse cardiovascular events, compared with carvedilol and other beta blockers. Although these findings suggest potential benefits of nebivolol in this population, prospective studies are needed to validate these observations.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question. Patients treated with nebivolol experienced greater reductions in blood pressure and a 27% lower risk of all-cause mortality compared to other beta blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: